We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > hAd5

News List

iosBio Inks Exclusive Vax Platform Pact for COVID-19 contractpharma
January 13, 2021
OraPro oral delivery vaccine platform technology enables oral administration of thermally-stable, viral vector vaccines.
ImmunityBio COVID-19 vaccine candidate shows protection of airways in non-human primates expresspharma
December 14, 2020
The hAd5-COVID-19 candidate is designed to address a potential problem that may emerge when first-generation adenoviral platforms are used as vaccine vectors: vaccine inactivation due to pre-existing immunity to the vector itself.
US FDA authorises phase 1 trial of ImmunityBio’s COVID-19 vaccine candidate hAd5 expresspharma
October 16, 2020
Ongoing development proceeding for oral, inhalational and intranasal administration of hAd5.